Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (47)	3/4/1998 6:12:00 PM
From: Meisterama	Read Replies (1) \| Respond to of 2887

Jeffrey, Your post is very reasonable. Too many times, on these SI boards, one sees posts from folks claiming to have close contact with a firm's CEO, going on and on about how "the CEO predicts this" and "the CEO believes that" and "the CEO privately tells me whatever." I've worked with plenty of business owners, and none of them has ever said to me, prior to their failure, "You know, Tom, this company is going nowhere and I have no confidence in my leadership." The good CEO is SUPPOSED to be the true believer, the cheerleader, no matter what. I think we are all wise to take positive CEO pronouncements, whether public or private, with a grain of salt. Still, I VERY much appreciate your sharing your insights on this board--your rational tone speaks well of your credibility.

To: Jeffrey L. Henken who wrote (47)	3/4/1998 7:29:00 PM
From: Aishwarya	Respond to of 2887

Jeffery It really takes a long time to establish a good amount of patents and even longer to get FDA approval. Since its inception in 1938, regulation of the medical device industry by the Food and Drug Administration has increased in scope, detail, and cost to the American people. Historically, legislative authority and regulatory stringency have made several discreet leaps, each prompted by shocking revelations widely disseminated by the news media. To demonstrate their devotion to protecting the public health, legislators and regulators have augmented the regulations, emphasizing the alleged benefits and disregarding the negative consequences for the industry and the patients it ultimately serves. In the past four years the FDA has drastically slowed the rate at which it approves new or improved medical devices. It has pursued an aggressive enforcement strategy that treats all regulated firms as suspected felons, restricting its communication and cooperation with them and substantially increasing the number of punitive actions. In response, increasing numbers of firms have moved their operations abroad or begun planning to do so. The FDA's regulation of medical devices has produced little if any benefit but imposed large and increasing costs. Those costs are not just economic; they also include deaths and human suffering. Ideally, the laws authorizing the FDA's regulation of medical devices would be repealed. At a minimum, Congress should alter the FDA's authority, making the administration an agency for certifying products instead of an agency for outlawing products, micromanaging the operations of the device firms, and impeding innovation. This again leads to cash flow problems. Having said all of this i can say with confidence that this company survived through a lot of crap and it did not help being innovative. So they have recently shifted gears to towards a future in OEM sales and that may possibly hold the key to the gold. We did gooood today. Go ABMI Regards, Sri.